Related Experiment Videos
[A preliminary study on the role of interleukin-1 in chronic lung disease]
Abstract:
Pulmonary alveolar macrophages (PAM) obtained by bronchoalveolar lavage in 13 normal individuals, 17 lung cancer patients and 10 patients with chronic obstructive pulmonary disease (COPD) were incubated in vitro for 24 hours. Every specimen was divided into two portions and lipopolysaccharides were used to stimulate PAMs to produce interleukin-1 (1L-1) in one. The levels of 1L-1 in normal subjects were 5547.65 +/- 2420.42 cpm/10(6) cells (stimulated) and 718.46 +/- 472.25 (unstimulated), which were higher than the 2733.20 +/- 1611.17 (stimulated, P less than 0.01) and 327.57 +/- 226.86 (unstimulated, P less than 0.05) in lung cancer patients, but lower than that of 8716.26 +/- 2977.66 (stimulated, P less than 0.05) in COPD patients. The enhanced 1L-1 activity in COPD patients might contributed to the active inflammatory process and tissue destruction of COPD. Our findings that 1L-1 activity in patients with bronchogenic carcinoma was decreased may reflect the local immune deficiency in malignant disease. The release of 1L-1 by PAMs stimulated by smoking was suggested to be associated with the development of COPD, but its role in immune response has to be determined.
Insights
Pulmonary alveolar macrophages (PAMs) release less interleukin-1 (IL-1) in lung cancer patients but more in COPD patients, suggesting altered immune responses in these lung diseases.
Area of Science:
- Immunology
- Pulmonology
- Cell Biology
Context:
- Pulmonary alveolar macrophages (PAMs) play a crucial role in lung immunity.
- Interleukin-1 (IL-1) is a key cytokine involved in inflammatory processes.
- Lung cancer and Chronic Obstructive Pulmonary Disease (COPD) are associated with altered immune responses.
Purpose:
- To investigate the production of Interleukin-1 (IL-1) by PAMs in normal individuals, lung cancer patients, and COPD patients.
- To compare IL-1 levels in stimulated and unstimulated PAMs across these groups.
Summary:
- PAMs from normal subjects produced significantly higher levels of IL-1 compared to lung cancer patients.
- COPD patients exhibited enhanced IL-1 production by PAMs compared to normal subjects and lung cancer patients.
- IL-1 levels in lung cancer patients were significantly lower, potentially indicating local immune deficiency.
Impact:
- Decreased IL-1 activity in lung cancer may reflect immune evasion strategies of malignant cells.
- Enhanced IL-1 activity in COPD may contribute to the inflammatory processes and tissue destruction characteristic of the disease.
- Smoking-induced IL-1 release by PAMs is implicated in COPD development, warranting further investigation into its immune role.